ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 30, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 30, 2011
News
Obama Initiates Partnership to Reinvigorate Manufacturing
By Erik Greb
President Obama unveiled an Advanced Manufacturing Partnership designed to reinvigorate the country's manufacturing sector.
IPEC Federation Issues Statement of Phthalate Use
By Patricia Van Arnum
The IPEC Federation has issued a statement on the use of phthalates in pharmaceutical products in response to reports of adulteration of certain nutritional supplements, vitamins, foods, and beverages imported from Taiwan.
EMA Stakeholder Forum on Pharmacovigilance
By Rich Whitworth
The European Medicines Agency (EMA) has held a second forum regarding the implementation of new pharmacovigilance legislation, which gave stakeholders the opportunity to discuss their expectations on various aspects of the new legislation's execution.
Pharma R&D Concerns
By Stephanie Sutton
Industry analysts have highlighted the pharma industry's high rate of Phase III drug terminations and significantly reduced R&D spending.
Week of June 27, 2011: Company and People Notes: Roche Establishes R&D Institute in France; Sanofi Appoints Peter Guenter as Senior Vice-President, Europe; and More.
Roche Establishes R&D Institute in France; Sanofi Appoints Peter Guenter as Senior Vice-President, Europe; and More.
Regulatory Roundup: FDA Publishes Final Guidance on Dissolution Testing
FDA Publishes Final Guidance on Dissolution Testing.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here